BeiGene Ltd (NAS:BGNE)
$ 172.85 1.82 (1.06%) Market Cap: 18.64 Bil Enterprise Value: 16.91 Bil PE Ratio: 0 PB Ratio: 5.37 GF Score: 70/100

Beigene Ltd to Discuss Final Results of the ALPINE Trial Late-Breaker Presentation Transcript

Dec 13, 2022 / 08:00PM GMT
Release Date Price: $208.07 (+1.85%)
Operator

Presentation
Dec 13, 2022 / 08:00PM GMT

=====================
Corporate Participants
=====================
* John V. Oyler
BeiGene, Ltd. - Co-Founder, Executive Chairman & CEO
* Josh Neiman
BeiGene, Ltd. - Senior VP, Chief Commercial Officer of North America & Europe
* Kevin C. Mannix
BeiGene, Ltd. - SVP of IR.
* Mehrdad Mobasher
BeiGene, Ltd. - Chief Medical Officer of Hematology

=====================
Conference Call Participants
=====================
* Andrew Scott Berens
SVB Securities LLC, Research Division - Senior MD of Medical Supplies and Devices & Senior Research Analyst
* Jennifer Brown
* Mazyar Shadman

=====================

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot